February 2023
Derivation of a Point of Departure from In Vitro Methods for use in Skin Sensitization Risk Assessment Pt 1
February 7, 2023This webinar explores the use of Non-Animal Methodologies to derive a Point of Departure (predicted LLNA EC3) which can be used to evaluate the skin sensitization potency as well as downstream use for risk assessment. Presenters include: Dr. Argel Islas-Robles (Study Director and Toxicologist, IIVS) and Dr. Andreas Natsch (Senior Research Fellow, Givaudan)....
IIVS Leadership Newsletter
February 3, 2023Please join me in congratulating Amanda Ulrey and Kristie Sullivan on their new roles as they work with Hans Rabe, Senior Vice President and Chief Operation Officer, and the rest of the IIVS team to further the IIVS mission of advancing the use and acceptance of non-animal approaches worldwide....